Intuitive is the dominant public surgical robotics franchise and belongs in any serious robotics basket.
Side-by-side research view
Compare names across metrics and research quality
Use up to 4 U.S.-listed names from this dashboard to compare valuation, growth, cash flow, balance-sheet strength, and the curated investment case in one place.
1 stocks in current compare
4 max names side by side
25 shared metrics lined up
Build a compare set
Enter comma-separated tickers from the dashboard universe. Duplicate tickers are ignored automatically.
Price
$437.75
1D change
-1.32%
Market cap
$151.74B
Sector
Healthcare
| Metric | ISRG |
|---|---|
| Price | $437.75 |
| 1D Change | -1.32% |
| Market Cap | $151.74B |
| Enterprise Value | $147.83B |
| Trailing P/E | 52.9 |
| Forward P/E | 35.1 |
| PEG Ratio | 2.00x |
| Price / Sales | 13.1 |
| EV / Revenue | 12.8 |
| Revenue Growth | 21.7% |
| Earnings Growth | -23.6% |
| Gross Margin | 66.6% |
| Operating Margin | 31.7% |
| Net Margin | 25.5% |
| ROE | 17.9% |
| Free Cash Flow | $3.43B |
| FCF Margin | 29.7% |
| Debt / Equity | — |
| Current Ratio | 3.33x |
| Dividend Yield | 0.00% |
| Next Earnings | Jan 21, 2027 |
| Quarterly Revenue | $3.05B |
| Revenue QoQ | +5.4% |
| Quarterly Net Income | $522.8M |
| Net Income QoQ | -36.1% |
ISRG thesis lens
Surgical robotics leader
Why it could benefit
- Intuitive is the dominant public surgical robotics franchise and belongs in any serious robotics basket.
- Its installed base, procedure growth, and recurring instruments model create a stronger moat than most robotics names.
- This adds a high-quality medical robotics angle that is less tied to data-center spending or industrial cycles.
Moat / edge
- Large installed base and deep surgeon training ecosystem.
- Recurring revenue from instruments, accessories, and service.
- Years of lead time and brand strength in robotic-assisted surgery.
What to watch
- Procedure growth and system placements.
- Adoption of newer da Vinci platforms and adjacent products.
- Gross-margin resilience as the business scales.
Key risks
- Premium valuation can leave less room for execution misses.
- Hospital capital-spending cycles still matter.